Pr. Rebecca Deprez-Poulain

Rebecca Deprez-Poulain, PharmD, PhD is Full Professor of Medicinal Chemistry and Drug Discovery at the School of Pharmacy in Lille. She did her PhD under the supervision of Pr Tartar (1996-1999) on combinatorial chemistry applied to lead discovery at the biotech CEREP. Since 2003, she has supervised the PhD projects of 6 students and 15 Master students. She is involved in many actions to promote research at the undergraduate level and manages the websites of the students majoring in the industry field ( at the School of Pharmacy as well as a dedicated site on insulin degrading enzyme ( Her research expertise is in the field of the modulation of metalloproteases. Her team has contributed in the field by disclosing the first inhibitors of the malarial aminopeptidase PfAM1 (J. Med. Chem 2007 & 2012), the first exosite binders of Insulin-Degrading Enzyme (Eur. J Med. Chem 2015), the first catalytic-site inhibitor of Insulin Degrading Enzyme tested in vivo (Nature Comm. 2015) and the first plasma-stability study of hydroxamates (J. Med. Chem 2009). Pr Deprez-Poulain has been awarded the joined French Society of Medicinal Chemistry & Servier Prize (2009) and the Foundation for Medical Research of North of France (2007) and several grants on this matter including a Hubert Curien Partnership grant on the current project. She has published several book chapters, 1 patent and 45 papers in peer-reviewed international journals, among which 7 J. Med. Chem, 1 Nat. Comm with 850 citations and an h factor of 16. She is a member of the international organizing committee of the 2016 EFMC-ISMC in Manchester.Pr Deprez-Poulain has been nominated as a member of the prestigious Institut Universitaire de France in Oct 2015. Her team is part of the drug discovery lab affiliated to the University of Lille, the Institut Pasteur de Lille and INSERM, which has been A-graded by the French Agency of Evaluation of Research.